LeMaitre Vascular Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw 10% organic sales growth, led by Artegraft and strong EMEA/APAC performance, while EPS rose 23% and gross margin reached 72.1%. Guidance was trimmed to 11% organic growth due to FX, export delays, and supply constraints, but profitability and cash flow remain robust.
-
Q1 2026 delivered 11% sales growth, 72.7% gross margin, and 42% EPS growth, driven by strong performance across all product categories and geographies. Artegraft led growth, with international sales expected to more than double in 2026. Full-year guidance was raised for revenue, margins, and EPS.
Fiscal Year 2025
-
Q4 2025 saw 16% sales growth, 71.7% gross margin, and 47% operating income growth, with strong international expansion and product launches. 2026 guidance projects 12% sales growth, 21% adjusted operating income growth, and continued margin expansion.
-
Q3 delivered 12% organic growth, record margins, and strong cash flow, with biologics and international launches outperforming expectations. Full-year guidance was raised for revenue, operating income, and EPS, despite headwinds from a catheter recall and FX.
-
Q2 2025 saw 15% sales growth, 70% gross margin, and 16% EPS growth, with strong performance in catheters, grafts, and international markets. Full-year guidance was raised across all key metrics, and new product launches and regulatory progress are expected to drive continued growth.
-
Q1 2025 saw 13% organic sales growth, record results across all product lines, and a raised 2025 sales guidance to $245 million. Gross margin improved to 69.2%, and the company expanded its sales force and direct international presence, with Artegraft's European launch imminent.
Fiscal Year 2024
-
Q4 2024 saw double-digit sales and earnings growth, margin expansion, and strong cash generation, driven by product and geographic gains, sales force investments, and pricing actions. 2025 guidance calls for continued robust growth, margin improvement, and strategic expansion.
-
Q3 2024 saw 16% sales growth and 49% EPS growth, driven by strong performance in grafts and international markets, with gross margin up to 67.8%. Guidance for Q4 and full-year 2024 was raised, and the company continues to expand direct sales channels and pursue regulatory approvals.
-
Q2 2024 saw 12% organic sales growth and 44% EPS growth, with strong performance across product lines and regions. Gross margin rose to 68.9%, and full-year guidance was raised for both sales and EPS. Regulatory progress and sales force expansion support continued growth.